Otilonium

Summary

Otilonium (CHEMBL1433361) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 483.7 Da · C29H43N2O4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1433361
Name	Otilonium
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	72093
Molecular formula	C29H43N2O4+
Molecular weight	483.7
InChIKey	NQHNLNLJPDMBFN-UHFFFAOYSA-O

SMILES: CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC

IUPAC name: diethyl-methyl-[2-[4-[(2-octoxybenzoyl)amino]benzoyl]oxyethyl]azanium

Also known as: Octylonium, Otilonium cation, Otilonium ion, SID26756890, Otilonium, Otilonium Bromide

Parent form; salt/anhydrous children: CHEMBL2103773

Patent coverage: 26 distinct patent families (44 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 42 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Histone-lysine N-methyltransferase 2A.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02576340	PHASE4	COMPLETED	Spasmolytic in Upper Gastrointestinal Endoscopy
NCT04270487	PHASE4	COMPLETED	The DOMINO Trial: Diet Or Medication in Irritable Bowel syNdrOme

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).